# OnCo record paper-momentum-momelotinib-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-momentum-momelotinib-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-momentum-momelotinib-lancet-2023" ;
  schema:name "MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor"@en ;
  schema:description "A JAK inhibitor that also blocks the anaemia-driving ACVR1 pathway improved symptoms and spleen size without worsening, and often improving, anaemia in previously treated patients."@en ;
  schema:url <https://onco.cc/key-papers/paper-momentum-momelotinib-lancet-2023/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=MOMENTUM%20momelotinib%20danazol%20myelofibrosis%20anaemia%20Verstovsek%20Lancet%202023>, <https://clinicaltrials.gov/study/NCT04173494> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(22)02036-0> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Verstovsek S, Gerds AT, Vannucchi AM, et al." ;
  onco:related <https://onco.cc/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/> ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:targets <https://onco.cc/targets/jak2/> ;
  onco:drugs <https://onco.cc/drugs/momelotinib/>, <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/pacritinib/> ;
  onco:companies <https://onco.cc/companies/gsk/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/lancet/> .